News in brief

ChromaDex’s new deal with Brazilian Biosciences National Laboratory could lead to ‘rapid commercialization of novel natural products’

ChromaDex’s new deal with Brazilian Biosciences National Laboratory could lead to ‘rapid commercialization of novel natural products’

A new agreement between Chromadex and the Brazilian Biosciences National Laboratory (LNBio) to evaluate ChromaDex's natural product libraries could lead to ‘rapid commercialization of novel natural products for food, beverage, cosmetic or pharmaceutical applications’.

The collaboration will see Chromadex provide its natural product libraries for screening, as well as the natural product chemistry expertise to continue the development of any identified candidates into commercial opportunities.  For its part, LNBio will screen those natural product libraries, as well as continue performing assays in enzymes, cells and organisms related to the discovery of chemical entities that are the object of this collaboration.

According to Chromadex: “[The] collaboration [will] screen [the] natural product libraries against certain molecular targets and phenotypic assays with the intent of identifying high value, possibly patentable natural products for specific therapeutic indications”. 

“ChromaDex's expertise in developing natural product libraries, and natural products chemistry, as well as its success in commercializing novel, branded ingredients, makes ChromaDex the ideal partner for this type of high throughput screening collaboration,” said Kleber Gomes Franchini, Director of LNBio. 

“If successful, this collaboration could lead to rapid commercialization of novel natural products for food, beverage, cosmetic or pharmaceutical applications.”

Frank Jaksch, Jr., founder and CEO of ChromaDex, said his company’s catalog offers thousands of very unique phytochemical compounds primarily isolated from botanicals.

“We are very excited to start this collaboration with LNBio, as this program will allow ChromaDex to extract value from the natural products library we have been developing over the past 15 years”

Related News

ChromaDex signs marketing deal with consulting firm

ChromaDex signs marketing deal with consulting firm

Niagen supports mitochondrial health, ChromaDex says.

Australian institute to study ChromaDex's Niagen ingredient in mitochondrial respiratory conditions

Cyanotech hires exec for newly created COO position

Cyanotech hires exec for newly created COO position

$5 million in additional funding will help ChromaDex bridge through to profitability, CEO says

$5 million in additional funding will help ChromaDex bridge through to profitability, CEO says

ChromaDex succeeds in boosting ingredient sales by 182%  in face of continuing losses

ChromaDex succeeds in boosting ingredient sales by 182% in face of continuing losses

Frank Jaksch, CEO of Chromadex

ChromaDex extends earnings streak, cuts losses in half

HPN's N(R) product to support neuroprotection in contact sports - the only commercial product currently available, but more are coming, says Frank Jaksch.

Chromadex CEO: ‘We think Niagen has a much bigger market, like omega-3’

Chromadex CEO: 'If we need to spend millions of dollars to develop an ingredient pipeline, we will do that'

Chromadex CEO: 'If we need to spend millions of dollars to develop an ingredient pipeline, we will do that'

DSM Venturing strategically invests in ChromaDex

DSM Venturing strategically invests in ChromaDex